Emanuel Necas

Dr. Emanuel Necas

orcid

Research Focus & Metrics

Academic Career Length

58Years (1969-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Physiological Research
Verified
Journal Article
Closed access
MVM Vokurka
M Vokurka
JKJ Krijt
J Krijt
KŠK Šulc
K Šulc
ENEmanuel Necas
Emanuel Necas
Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages. Iron, anemia, hypoxia, and inflammation were reported to influence hepcidin expression. To investigate regulation of the expression of hepcidin and other iron-related genes, we manipulated erythropoietic activity in mice. Erythropoiesis was inhibited by irradiation or posttransfusion polycythemia and stimulated by phenylhydrazine administration and erythropoietin. Gene expression of hepcidin and other iron-related genes (hemojuvelin, DMT1, ferroportin, transferrin receptors, ferritin) in the liver was measured by the real-time polymerase chain reaction. Hepcidin expression increased despite severe anemia when hematopoiesis was inhibited by irradiation. Suppression of erythropoiesis by posttransfusion polycythemia or irradiation also increased hepcidin mRNA levels. Compensated hemolysis induced by repeated phenylhydrazine administration did not change hepcidin expression. The decrease caused by exogenous erythropoeitin was blocked by postirradiation bone marrow suppression. The hemolysis and anemia decrease hepcidin expression only when erythropoiesis is functional; on the other hand, if erythropoiesis is blocked, even severe anemia does not lead to a decrease of hepcidin expression, which is indeed increased. We propose that hepcidin is exclusively sensitive to iron utilization for erythropoiesis and hepatocyte iron balance, and these changes are not sensed by other genes involved in the control of iron metabolism in the liver.

1 August 1979 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
PPPřemysl Poňka
Přemysl Poňka
JBJitka Borová
Jitka Borová
JNJan Neuwirt
Jan Neuwirt
OFOta Fuchs
Ota Fuchs
ENEmanuel Necas
Emanuel Necas

1 June 2010 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
MPMilana Pokorná
Milana Pokorná
ENEmanuel Necas
Emanuel Necas
JKJaroslav Kratochvíl
Jaroslav Kratochvíl
RSRoman Skřipský
Roman Skřipský
MAMichal Andrlík
Michal Andrlík
OFOndrej Franěk
Ondrej Franěk

7 April 2011 in Blood
Verified
Journal Article
Closed access
PDF file
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
NCNikola Curik
Nikola Curik
PBPavel Burda
Pavel Burda
PBPetra Bašová
Petra Bašová
VKVojtech Kulvait
Vojtech Kulvait
TSTomas Stopka
Tomas Stopka
Elevated levels of microRNA miR-155 represent a candidate pathogenic factor in chronic B-lymphocytic leukemia (B-CLL). In this study, we present evidence that MYB (v-myb myeloblastosis viral oncogene homolog) is overexpressed in a subset of B-CLL patients. MYB physically associates with the promoter of miR-155 host gene (MIR155HG, also known as BIC, B-cell integration cluster) and stimulates its transcription. This coincides with the hypermethylated histone H3K4 residue and spread hyperacetylation of H3K9 at MIR155HG promoter. Our data provide evidence of oncogenic activities of MYB in B-CLL that include its stimulatory role in MIR155HG transcription.

6 September 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
VPVit Pospisil
Vit Pospisil
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
JKJuraj Kokavec
Juraj Kokavec
JRJana Rybarova
Jana Rybarova
Filipp Georgijevic SavvulidiFilipp Georgijevic Savvulidi
Filipp Georgijevic Savvulidi
TSTomas Stopka
Tomas Stopka
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 January 2006 in Folia Biologica
Verified
Journal Article
Open access
PDF file
ISIgor Shchemelinin
Igor Shchemelinin
LŠLuděk Šefc
Luděk Šefc
ENEmanuel Necas
Emanuel Necas
Protein phosphorylation is known to play an important role in various cellular processes such as cell division, metabolism, survival and apoptosis. It is driven by specific enzymes, tyrosine and serine-threonine protein kinases. Human protein kinases constitute a complicated system with intricate internal and external interactions. The complexity and sophistication of the system implies its vulnerability. Alterations in functions of these enzymes may launch series of pathological changes within the cell and as a result cause diseases. Protein kinases have been shown to be involved in various pathological processes, first of all malignancies. Deregulation of different protein kinases has been found in chronic myelogenous leukaemia, gastrointestinal stromal tumours, various other sarcomas and cancers as well as non-malignant disorders. Therefore, they are regarded as important effectors in human pathology and represent prospective therapeutic targets.